Severe BPD and infection leave different immune fingerprints in preterm infants
Preterm birth does not simply accelerate exposure to the outside world; it compresses immune development into a period when inflammation, infection, and lung injury can redirect it. In a longitudinal study of residual whole blood from 38 preterm infants, investigators tracked immune composition every two weeks and compared those patterns with 10 term infants at birth. The result was not a single preterm immune phenotype, but two very different inflammatory trajectories shaped by the type of neonatal complication.
One path was dominated by severe bronchopulmonary dysplasia, where the immune system moved toward a progressive Th17-polarized profile. The other appeared after systemic bacterial or viral infection, where some infants mounted unusually strong CD8+, CD4+, and γδ T cell responses that did not fade quickly once infection resolved.
Th17 skewing tracks with severe bronchopulmonary dysplasia
Among preterm infants with severe BPD, immune profiling showed a progressive rise in Th17-polarized CD4+ T cells, neutrophils, and Th17-related cytokines compared with age-matched infants who had moderate BPD. The pattern fits the biology of chronic airway and systemic inflammation. Th17 pathways are deeply involved in neutrophil recruitment and barrier inflammation, so their expansion in severe BPD offers a plausible immunologic link to the persistent lung injury that defines the disorder.
This was not a static snapshot. The signal strengthened over time, which matters in a disease where early pulmonary injury can become self-reinforcing. Repeated inflammatory stimulation during a stage of immune immaturity may nudge the neonatal immune repertoire toward sustained myeloid and Th17 activation rather than balanced maturation.
A persistently inflamed lung can train the circulating immune system, not just the airway.
Infection triggered broad T cell expansion that outlasted illness
The infection-associated pattern looked different from the BPD signal. In some preterm infants with systemic bacterial or viral infections, immune profiling captured exceptionally robust T cell responses across several lineages, including CD8+, CD4+, and γδ T cells. Those responses were not broad in the casual sense; they were biologically focused, with oligoclonal expansion and terminal differentiation indicating that selected clones had expanded aggressively in response to antigenic pressure.
Even after clinical infection had resolved, coordinated shifts in plasma cytokines remained in place. The persistence of those cytokine changes suggests that a neonatal infection can leave a longer immunologic footprint than the acute illness alone would imply. In a developing immune system, that kind of prolonged reprogramming may alter how later inflammatory exposures are interpreted at the cellular level.
Longitudinal profiling revealed immune development is not uniform in prematurity
The study design deserves attention because it followed infants over time rather than freezing immune development into a single measurement. Residual whole blood collected every two weeks allowed the investigators to see evolution, not just association. That approach is especially important in preterm infants, whose immune status can shift rapidly as lung disease, infection, transfusion exposure, and intensive care interventions unfold in parallel.
The contrast with term infants at birth provided a useful developmental anchor. Preterm immune trajectories did not simply look immature relative to term newborns; they diverged according to comorbidity. Severe BPD pushed toward one inflammatory program, while systemic infection triggered a highly activated adaptive response with durable consequences.
Oligoclonality points to antigen-driven expansion in early life
Figure-level data reinforced the intensity of the infection-related response. T cell receptor sequencing showed a massive first-in-life T cell reaction that was oligoclonal. In practical terms, that means a limited number of clones dominated the response rather than a diffuse, evenly distributed activation of many different T cells. The productive Simpson clonality index, the frequency of TCRs found in more than three clonotypes, the occupied repertoire score, and the distribution of CDR3 lengths all pointed toward a repertoire reshaped by strong antigen selection.
For neonatal immunology, this is a critical point. Early-life immune responses are often framed as blunted or underdeveloped, yet these data show that preterm infants can also generate strikingly concentrated effector responses when the stimulus is severe enough. The immune system in prematurity is not merely weak; it is plastic, and in some settings it is easily redirected.
Different comorbidities, different targets for intervention
The immediate bedside implication is not that one inflammatory pathway explains all prematurity-related disease. It is that severe BPD and systemic infection appear to imprint the immune system in distinct ways, which opens the door to more specific intervention strategies. A Th17-skewed inflammatory state in chronic lung disease suggests a different therapeutic logic than the highly clonal antiviral or antibacterial T cell expansion seen after infection.
That distinction matters because the same infant may pass through multiple inflammatory states during a short NICU course. A lung-centered disease process may require suppression of maladaptive myeloid and Th17 activation, while postinfectious immune remodeling may require different surveillance and perhaps a better understanding of how long adaptive immune activation persists after the pathogen is gone. The study does not define those interventions, but it does define the problem with unusual clarity: preterm comorbidities are not immunologically equivalent.
The work also raises a practical question for pediatric immunology and neonatology. If longitudinal immune profiling can distinguish infants whose immune systems are drifting toward chronic Th17 inflammation from those with prolonged antigen-driven T cell expansion, then blood-based profiling may eventually help identify which infant is on which path before injury becomes entrenched. For now, the study stops short of treatment guidance, and it does not establish which immune changes are reversible or predictive of later outcomes. What it does establish is that the preterm immune system records early complications in more than one way, and those records persist well beyond the first insult.